Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma 2Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, T-Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1HTLV-I Infections 1Diabetes Mellitus, Insulin-Dependent, 10 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Daclizumab × Clear all
NCT00847106 2009-02-19

Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients

Radboud University Medical Center

Phase 1/2 Completed
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡